Summary
Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Description
THE PHARMACEUTICAL MARKET: BRAZIL - REVIEW
The Brazilian pharmaceutical market is the third largest in the Americas region, behind the USA and Canada; it ranks first in the Latin American region. Pharmaceutical demand will continue to rise, fuelled by increasing disposable income, therefore the market outlook is positive for the 2011-2016 period. Competition among the five leading pharmacy chains is fierce, and the sector has been consolidated by a recent wave of mergers. In September 2011, Drogaria Sao Paulo, the leader in the state of Sao Paulo, and Drogarias Pacheco, the leader in Rio de Janeiro, announced a merger, creating what will be the largest pharmacy chain in Brazil, DPSP. This merger took place after the merger between Drogasil and Droga Raia, announced in August 2011, creating the second largest pharmacy chain, Raia Drogasil.
Generics are expected to have a pharmacy market share of 20.0% by value and 25.0% by volume in 2011. Major developments in 2011 include Aspen's acquisition of six medicaments owned by a local company in August 2011; Prazzi-Donaduzzi's plans to increase production, announced in July 2011; a distribution agreement between Novartis' Sandoz and Sanofi's Medley, valid from June 2011; and Stride Arcolab's joint-venture with a local company, announced in January 2011. Major developments in 2009-2010 included Pfizer's purchase of 40.0% of Teuto in October 2010, Valeant's two acquisitions in May 2010 and April 2010, Sanofi's acquisition of Medley in 2009, and Hypermarcas acquisition of Neo Quimica in 2009. As a result, multinationals have increased their pharmacy market share and they represented 40.0% of the total in 2010.
Local producers have increased their investments to strengthen their position. Ache, which lost the race to acquire Mantecorp but acquired 50.0% of Melcon in November 2010, has tried to form a joint-venture with GlaxoSmithKline in 2011, but this has been aborted. Biolab established an R&D unit in 2010. Cristalia signed an agreement to purchase an Argentine company in September 2011. Additionally, the company signed a joint-venture with Eurofarma to launch Supera in August 2011. EMS has announced investments of R$360.0 million (US$205.3 million) in three new manufacturing plants. Eurofarma announced the acquisition of Segmenta in December 2010. The company also invested R$450.0 million (US$233.2 million) in its manufacturing complex in 2010. Additionally, Eurofarma strengthened its international position in 2009-2010. Hypermarcas reorganised its business units in August 2011, following a number of recent acquisitions, the most notable being that of Mantecorp.
ANVISA published a new regulation for biologic products in December 2010. Several local companies have recently announced plans to strengthen their capabilities: Biomm plans to start the construction of an insulin plant in 2012; Halex Istar inaugurared a manufacturing unit for the production of sera in September 2011; and Hebron, which inaugurated a subsidiary in the USA in August 2011, plans to start the construction of a haemoderivatives manufacturing plant in 2012. In September 2011, EMS also signed a product licensing agreement with the South Korean company ISU ABXIS. Foreign companies have also showed interest in the biologic market. Amgen, for example, acquired a local producer in April 2011, and reacquired a number of products previously licensed to Mantercorp, which was acquired by Hypermarcas in January 2011. Novartis, via Sandoz, plans to launch the biosimilar Omnitrope in 2011.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
The Pharmaceutical Market: Brazil published by Espicom Business Intelligence in January 31, 2013. This report consists of 192 Pages and the price starts from US $ 1295.
The contents of this page may be different from the latest version. Please contact us for details.
